Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE8: Darolutamide + SBRT in Oligometastatic CRPC
NCT06276465Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Oct 2024
- Primary completion
- Oct 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by Unicancer. Started Oct 2024; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06276465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276465.